Hypertension | Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Hypertension research study
What is the primary objective of this study?
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.
Who is eligible to participate?
Inclusion Criteria: - Male and female hypertensive participants who were previously studied in SCOR program. Exclusion Criteria: - Diabetes - Taking other medications beside thyroid or estrogen supplements.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Lisinopril, Atenololonce a day for 14 weeks
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Active, not recruiting
Start Date: January 2007
Completed Date: March 2018
Primary Outcome: One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
Study sponsors, principal investigator, and references
Principal Investigator: Gordon H. Williams, MD
Lead Sponsor: Brigham and Women's Hospital
Collaborator: University of Utah